The Blackstone Group, a major US private equity firm, has announced the acquisition of Takeda Consumer Healthcare Company (TCHC), a subsidiary of Takeda Pharmaceutical. Investment funds and other industries have been putting out feelers toward the pharmaceutical sector in recent…
REGULATORY
Stemirac Fetches 15 Million Yen Price Tag, Peak Sales Put at 3.7 Billion Yen
Stemirac, the first stem cell therapy for spinal cord injury conditionally approved in Japan late last year, will join the NHI reimbursement price list on February 26, carrying a price tag of nearly 15 million yen. However, peak sales are…
To read the full story
Related Article
- Medipal’s Subsidiary to Distribute Stemirac in Japan
April 9, 2019
- MHLW Acknowledges Need to Ponder Rules for “Regenerative Medicines”: Official
February 21, 2019
- Nipro to Strive for Stable Supply of Stemirac, 1st Stem Cell Therapy for Spinal Cord Injury
January 7, 2019
- Japan Gives Conditional OK to 1st Stem Cell Therapy for Spinal Cord Injury
December 28, 2018
REGULATORY
- MHLW to Set Up Study Group to Investigate Formulary Initiatives at Hospitals: Pharmaceutical Management Director
September 25, 2020
- MHLW Explains Budget Request to LDP Lawmakers, Members Vigilant about Handling of Price Survey Results
September 25, 2020
- MHLW to Request Budgets for Survey on Prescribing Status, Safety of COVID-19 Meds Using MID-NET Database
September 25, 2020
- Health Minister Ready to Discuss Telemedicine Rollout, but Wants to Ensure Peace of Mind for Patients
September 24, 2020
- PMDA to Continue Remote GCP/Compliance Inspections through End of March 2021
September 24, 2020
Measures focusing on risk management should be necessary to prevent disruptions in API supplies, Prof. Hiroyuki Sakamaki of Kanagawa University…
Nearly a year after the introduction of the Ministry of Health, Labor and Welfare’s (MHLW) drug promotion guidelines in April…
Advancements in modified oligonucleotide technologies has been the key driver behind a spate of approvals in the oligonucleotide therapeutics space…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
The Ministry of Health, Labor and Welfare (MHLW) on November 27 added to the NHI price list Japan’s first biosimilars of Avastin (bevacizumab), Nesp (darbepoetin alfa), and Forteo (teriparatide). The NHI prices of first biosimilars are set at 70% of…
A total of 51 new drugs joined the NHI price list in 2019, which are expected to generate combined peak sales of 373 billion yen, according to Jiho’s tally of data submitted to a key reimbursement policy panel. The relatively…
Some seven years in the making, Japan’s Ministry of Health, Labor and Welfare (MHLW) finally rolled out a cost-effectiveness assessment…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…
Despite the worldwide focus on inclusivity and diversity, it will take immediate action to counteract Japan’s growing gender gap. Study after study has proven that companies with more women in senior roles perform better financially, gaining a competitive edge from…